JP2004525140A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525140A5
JP2004525140A5 JP2002574969A JP2002574969A JP2004525140A5 JP 2004525140 A5 JP2004525140 A5 JP 2004525140A5 JP 2002574969 A JP2002574969 A JP 2002574969A JP 2002574969 A JP2002574969 A JP 2002574969A JP 2004525140 A5 JP2004525140 A5 JP 2004525140A5
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
cycloalkenylalkyl
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002574969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525140A (ja
Filing date
Publication date
Priority claimed from CA 2342472 external-priority patent/CA2342472A1/en
Application filed filed Critical
Priority claimed from PCT/AU2002/000339 external-priority patent/WO2002076454A1/en
Publication of JP2004525140A publication Critical patent/JP2004525140A/ja
Publication of JP2004525140A5 publication Critical patent/JP2004525140A5/ja
Pending legal-status Critical Current

Links

JP2002574969A 2001-03-26 2002-03-20 ガンの治療方法及び該治療方法に使用する組成物 Pending JP2004525140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27843501P 2001-03-26 2001-03-26
CA 2342472 CA2342472A1 (en) 2001-03-30 2001-03-30 Ram having dynamically switchable addressing modes
PCT/AU2002/000339 WO2002076454A1 (en) 2001-03-26 2002-03-20 Method for treatment of cancer and compositions for use therein

Publications (2)

Publication Number Publication Date
JP2004525140A JP2004525140A (ja) 2004-08-19
JP2004525140A5 true JP2004525140A5 (enExample) 2006-01-05

Family

ID=25682475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574969A Pending JP2004525140A (ja) 2001-03-26 2002-03-20 ガンの治療方法及び該治療方法に使用する組成物

Country Status (4)

Country Link
US (1) US20050038022A1 (enExample)
EP (1) EP1379242B1 (enExample)
JP (1) JP2004525140A (enExample)
WO (1) WO2002076454A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164715A1 (en) 2000-07-10 2002-11-07 Lin Ji Chromosome 3p21.3 genes are tumor suppressors
WO2002067932A1 (en) 2001-01-11 2002-09-06 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
ES2425750T3 (es) * 2004-08-31 2013-10-17 Newsouth Innovations Pty Limited Inhibición del VEGF
ES2528363T3 (es) 2004-12-06 2015-02-09 Pitney Pharmaceuticals Pty Limited Tratamiento para el cáncer
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
TW200720255A (en) * 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP3383852A4 (en) * 2015-11-30 2019-08-28 Children's Medical Center Corporation COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
JP2018002619A (ja) * 2016-06-29 2018-01-11 国立大学法人 東京大学 オートファジー阻害剤
GB2559162A (en) * 2017-01-27 2018-08-01 Univ Bradford Compound for use in medicine
TW202214245A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 雙非癌藥物用於製備治療癌症之醫藥組合物的用途
CN113648308A (zh) * 2021-09-14 2021-11-16 东莞市人民医院 奥芬达唑作为抗卵巢癌药物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
AUPO727097A0 (en) * 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
AUPP332898A0 (en) * 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition
CA2344316A1 (en) * 1998-09-16 2000-03-23 Saira Sayed Singh Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
MXPA02002360A (es) * 1999-09-03 2002-07-30 Janssen Pharmaceutica Nv Formulacion veterinaria para administracion de un farmaco insoluble en agua a un animal objetivo mediante un sistema de distribucion de agua.
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Similar Documents

Publication Publication Date Title
TWI385160B (zh) 用於治療增生性疾病的化合物
US9175022B2 (en) Compounds for the treatment of proliferative disorders
ES2399241T3 (es) Compuestos de triazol que modulan la actividad de HSP90
US8188075B2 (en) Triazole compounds that modulate HSP90 activity
JP2022520061A5 (enExample)
JP2002525329A5 (enExample)
JP2007520452A5 (enExample)
JP2019507114A5 (enExample)
US8399435B2 (en) Compounds for the treatment of proliferative disorders
EP2059250A2 (en) Compounds for the treatment of angiogenesis
JP2006503805A5 (enExample)
JP2021523169A5 (enExample)
CN1283248C (zh) 包含埃坡霉素的组合及其药学应用
WO2018158175A1 (en) Combination of bub1 inhibitors
JP2003535874A5 (enExample)
RU2005108570A (ru) Лекарственное средство для лечения доброкачественных и злокачественных опухолевых заболеваний, содержащее производное дисоразола
JP2019529563A5 (enExample)
RU2024139605A (ru) Соединения пиридо[4,3-d]пиримидина
JP2005510556A5 (enExample)